Merit Med Sys Inc Stock Price, News & Analysis

The WRAPSODY FIRST Study revealed promising results for the WRAPSODY Endoprosthesis by Merit Medical Systems (MMSI), showing a 100% target lesion primary patency (TLPP) rate at 30 days and an 84.6% TLPP rate at 12 months among 46 subjects treated for arteriovenous access circuit stenosis. The study indicated a 65.9% access circuit primary patency (ACPP) rate at one year, supporting the device's safety and effectiveness. The company plans a large WAVE Study to further validate these results and pursue FDA approval.

Merit Medical Systems has launched the One-Vac™ Evacuated Drainage Bottle, a device designed to aspirate, remove, or sample body fluids. This innovative product is particularly beneficial for thoracentesis and paracentesis procedures. Its advanced features include an ergonomic handle for easy flow regulation and a durable construction to minimize spills. The launch, praised by early users, supports Merit's expanding drainage portfolio, reflecting the company's commitment to incorporating physician feedback and advancing technologies.

Merit Medical Systems, Inc. (NASDAQ: MMSI) reported Q2 2021 revenue of $280.3 million, a 28.4% increase from Q2 2020. GAAP net income was $4.9 million ($0.09/share), contrasting with a loss of ($19.1 million) last year. Non-GAAP net income reached $35.3 million ($0.62/share), up 103%. The company updated its full-year guidance, projecting net sales between $1,060 - $1,070 million, reflecting a growth of 9% - 10% year-over-year. Cash on hand increased to $70 million, while long-term debt decreased to $293 million.

Merit Medical Systems, Inc. (NASDAQ: MMSI) announced it will release its financial results for Q2 2021 on July 29, 2021, after market close. An investor conference call will follow at 5:00 p.m. Eastern time on the same day. The call can be accessed domestically at (844) 578-9672 and internationally at (508) 637-5656, with a live webcast available on merit.com. Founded in 1987, Merit manufactures disposable medical devices for interventional procedures and serves clients worldwide, employing about 6,500 people across multiple global locations.

Merit Medical Systems (NASDAQ: MMSI) reported Q1 2021 revenue of $248.9 million, up 2.2% from Q1 2020. The GAAP EPS stood at $0.19, a turnaround from a loss of ($0.06) in the previous year. Non-GAAP EPS increased to $0.52 from $0.38. The company's GAAP gross margin was 45.0%, up from 42.6% year-over-year. A strong cash flow of $29 million was generated. For FY 2021, Merit forecasts net revenue between $994 million and $1,014 million, anticipating modest growth in the cardiovascular and endoscopy segments.

Merit Medical Systems, Inc. (NASDAQ: MMSI) will announce its Q1 financial results for the period ending March 31, 2021, on April 29, 2021, after market close. The company will host a conference call at 5:00 p.m. Eastern Time on the same day, with details available on their website. Founded in 1987, Merit specializes in disposable medical devices for interventional procedures across various fields, including cardiology and oncology, serving a global client base.

SOUTH JORDAN, Utah, April 08, 2021 (GLOBE NEWSWIRE) -- Merit Medical Systems (NASDAQ: MMSI), a leader in disposable medical devices for interventional, diagnostic, and therapeutic procedures, will participate in the 20th Annual Needham Healthcare Conference. The event is set for April 15 at 2:15 p.m. ET, featuring a fireside chat with CEO Fred Lampropoulos and CFO Raul Parra. Merit Medical, headquartered in Utah, operates globally with a workforce of about 6,000, catering to hospitals and healthcare facilities across various regions.

Merit Medical Systems (NASDAQ: MMSI) has initiated its pivotal WAVE Study to assess the safety and effectiveness of the WRAPSODY Endovascular Stent Graft for treating dialysis outflow circuit stenosis or occlusion. The first two patients have been enrolled at RAC Surgery Center, Raleigh, NC. This multicenter study aims to recruit 357 patients across the U.S., Europe, Canada, and New Zealand, with a two-year follow-up. The WRAPSODY system, already holding a CE Mark, is designed to improve vascular access in over two million global hemodialysis patients, addressing common complications in dialysis procedures.

Merit Medical Systems reported Q4 2020 revenue of $258.0 million, nearly flat compared to Q4 2019. The company experienced a 1.0% decline in core revenue on a constant currency basis. The Q4 GAAP EPS stood at $0.27, recovering from a loss of ($0.08) the previous year. Non-GAAP EPS rose to $0.54 from $0.40. For the full year, revenue was $963.9 million, down 3.1%, while GAAP net income for Q4 was $15.4 million. Merit forecasts 2021 revenue between $990 million and $1.01 billion, reflecting a cautious optimism for recovery.